<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Entresto</title>
	<atom:link href="http://www.tapanray.in/tag/entresto/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>When Patents Meet Patients: Why India Revoked Novartis’ Vymada Patent</title>
		<link>http://www.tapanray.in/when-patents-meet-patients-why-india-revoked-novartis-vymada-patent/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=when-patents-meet-patients-why-india-revoked-novartis-vymada-patent</link>
		<comments>http://www.tapanray.in/when-patents-meet-patients-why-india-revoked-novartis-vymada-patent/#comments</comments>
		<pubDate>Thu, 18 Sep 2025 12:11:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Entresto]]></category>
		<category><![CDATA[ever greening]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revoked]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Vymada]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10971</guid>
		<description><![CDATA[India’s bold move against Novartis’ blockbuster heart drug patent highlights the country’s uncompromising balance between innovation incentives and affordable access to medicines. The Verdict That Stirred the Industry: On September 12, 2025, the Indian Patent Office revoked Novartis’ patent on Vymada (internationally known &#8230; <a href="http://www.tapanray.in/when-patents-meet-patients-why-india-revoked-novartis-vymada-patent/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/when-patents-meet-patients-why-india-revoked-novartis-vymada-patent/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Moving Beyond The Pill: No Longer An Option</title>
		<link>http://www.tapanray.in/moving-beyond-the-pill-no-longer-an-option-2/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=moving-beyond-the-pill-no-longer-an-option-2</link>
		<comments>http://www.tapanray.in/moving-beyond-the-pill-no-longer-an-option-2/#comments</comments>
		<pubDate>Sun, 12 Nov 2017 23:54:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[beyond]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[Entresto]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[measurable]]></category>
		<category><![CDATA[moving]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[option]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pill]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8520</guid>
		<description><![CDATA[Many of us would prefer to live, as long as possible, in the comfort zones of old paradigms, hoping to succeed in the same way as we had succeeded in the past. But the wheel of time keeps moving, triggering &#8230; <a href="http://www.tapanray.in/moving-beyond-the-pill-no-longer-an-option-2/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/moving-beyond-the-pill-no-longer-an-option-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>What Happens To Pharma’s Incredible Ride On The ‘Gravy Train’?</title>
		<link>http://www.tapanray.in/what-happens-to-pharmas-incredible-ride-on-the-gravy-train/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=what-happens-to-pharmas-incredible-ride-on-the-gravy-train</link>
		<comments>http://www.tapanray.in/what-happens-to-pharmas-incredible-ride-on-the-gravy-train/#comments</comments>
		<pubDate>Sun, 25 Sep 2016 23:42:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bans]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Entresto]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[gravy]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[incredible]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Jimenez]]></category>
		<category><![CDATA[Joe]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[ride]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[train]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7828</guid>
		<description><![CDATA[India continues to be one of the fastest growing pharmaceutical market of the world with its over 40 percent of the total pharmaceutical produce is exported around the world. Over half of the total exports constitute of formulations, and the &#8230; <a href="http://www.tapanray.in/what-happens-to-pharmas-incredible-ride-on-the-gravy-train/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/what-happens-to-pharmas-incredible-ride-on-the-gravy-train/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
